A pilot study to measure the clearance of replication-competent HIV-1 in resting memory CD4+ cells in HIV-1-infected subjects who receive enfuvirtide [Fuzeon (Rm)] plus oral combination antiretroviral therapy.

Next Previous
Trial Profile

A pilot study to measure the clearance of replication-competent HIV-1 in resting memory CD4+ cells in HIV-1-infected subjects who receive enfuvirtide [Fuzeon (Rm)] plus oral combination antiretroviral therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2013

At a glance

  • Drugs Enfuvirtide (Primary) ; Emtricitabine; Ritonavir; Saquinavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Apr 2012 Actual end date changed from Apr 2009 to May 2008 as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top